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Vesical clear cell adenocarcinoma is an uncommon tumour. The description of nearly all published cases focuses on histological
issues, providing few clinical particulars and limited followup. The treatment choice is resection. No publications have been found
regarding systemic treatments for advanced disease. We present a case of metastatic clear cell adenocarcinoma of the bladder
treated with chemotherapy.
1.Introduction
Most of the published cases of metastatic clear-cell adeno-
carcinoma of the bladder describe women in their ﬁfties or
sixties whounderwent total cystectomyasthe only treatment
[1]. This disease has also been described, to a lesser extent, in
both men and in an age range between 19 and 80 years old.
Most authors are typically specialists in pathology, and the
publications focus on the peculiar histology of the disease
and a study of the histogenesis as of two possible origins:
mesonephric or M¨ ullerian. The most common locations are
the neck of the bladder, the urethra and the posterior wall,
and there is often an urothelial component of the tumour
[2]. Thus, it has been suggested that the tumours are derived
from the mesonephros. The theory of M¨ ullerian origin
is based on three factors: its morphological similarity to
tumoursofthislineagewithinthefemalegenitaltract,onthe
factthatthetumorsarelargelyfoundinwomen,anditsasso-
ciation with endometriosis [3]. Immunohistochemical anal-
ysis of tumour samples supports both theories, so it has been
assumed that the embryonic origin varies with each case [4].
From a histological perspective, it is also important to
consider non invasive clear-cell adenoma as a diﬀerential
diagnosis [5]. Both conditions are well characterised from
a morphological viewpoint because they are recognisable
without further study by light microscopy [6]. Nevertheless,
both lesions present PAX8 expression that can help to diﬀer
them from urothelial carcinoma [7].
The clinical presentation is the same as that of urothe-
lial tumours: mictional syndrome, acute urinary retention,
and/or haematuria [1].
The usual treatment is surgical, with partial or radi-
cal cystectomy [1]. The subsequent published followup is
short—rarely as long as 10 months—with the longest being
30 months. As such, the prognosis of this entity is diﬃcult to
estimate.
Asinglecaseoflocallyadvancedtumourtreatedbypelvic
exenteration did not recur during 30 months of followup
[8]. In another case of extravesical spread, in which surgical
treatment was not contemplated, the evolution was very
poor, and the patient died eight months after diagnosis due
to metastatic disease [9]. Only one case of radiotherapy2 Chemotherapy Research and Practice
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Figure 1: (a) Clear-cell adenocarcinoma (mesonephric). Glandular growth pattern with the presence of atypical hobnail cells. (b) Clear-cell
adenocarcinoma(mesonephric).Invasionofthemuscularlayerofthebladderwall.(c)Samplefromtransurethralresectionwithtransitional
and clear-cell adenocarcinoma combination.
treatment alone has been described, resulting in complete
response of the localised disease [10].
Experience with chemotherapy is limited to an adjuvant
setting. The drugs used include Cisplatin and 5-Fluoracil
[1], Carboplatin and Methotrexate [11], and Adriamycin
and Cyclophosphamide [12], with or without radiotherapy.
However, because all of these instances are cases of adjuvant
treatment and had little followup, we are unable to evaluate
the disease sensitivity to chemotherapy.
2.CaseDescription
A 49-year-old woman developed mictional syndrome
attributed to infection in September 2005. The symptoms
did not improve with empiric antibiotic treatment, and she
was referred to the Urology Department. She was diagnosed
with a vesical tumour by cystoscopy in June 2006. It was
resected by a transurethral resection, and a report described
a mesonephric clear-cell adenocarcinoma (M9110/1 in the
ICD-9-CM classiﬁcation for malignant tumour morphol-
ogy). The sample did not include the muscular layer of the
bladder. Computerised tomography (CT) imaging was per-
formed,revealingathickeningofthevesicalwallandbilateral
adnexal cystic structures. The transurethral resection was
repeated, whereby the sample obtained was consistent with
clear-cell adenocarcinoma (Figure 1a) with inﬁltration into
the muscular layer (Figure 1b) of the bladder (pT2). It
was associated with areas of high grade transitional cell
carcinomanon-invasive(Figure 1c).Thetumourwaslocated
within the neck of the bladder and the left half of the trigone.
A CT scan demonstrated retroperitoneal nodes measuring
less than one centimetre and iliac adenopathy measuring
two centimetres. The patient underwent further surgery
on November 9, 2006 with resection of an endometriosic
ovarian cystic structure and an iliac adenopathy, which was
identiﬁed during surgery as metastatic, and thus the surgery
ended. The adenopathy was entirely inﬁltrated by clear-cell
adenocarcinoma, without transitional component.
After recovery, the patient was referred to the Medical
Oncology Department. During the ﬁrst visit, she presented
a PS (ECOG) of 1, with symptoms derived from the
vesical condition. In view of the lack of bibliographical
data concerning chemotherapy in metastatic disease, it
was decided to use a regimen for urothelial carcinoma of
the bladder with Cisplatin and Gemcitabine. Radiotherapy
was not considered because nodes were present outside of
the radiation ﬁeld. During the ﬁfth cycle, Cisplatin was
replaced with Carboplatin due to a poorly controlled emetic
syndrome. The best response after six cycles was radiological
stabilisation, and the treatment was terminated. Radiological
and clinical progression was observed three months later.
Thus,asecondlineoftreatmentwasinitiatedwithDocetaxel,
of which the patient received a total of ﬁve cycles, and
with radiological stabilisation after the third and subsequent
progression. Treatment was suspended in December 2007, at
which time it was decided to administer symptomatic and
support treatment.
In April 2008, the patient complained of back pain. A CT
scan revealed progression of the tumour into the primary
location and at nodal, liver, and bone level, with medullary
compressionatD12.Shewasurgentlyadministeredpalliative
radiotherapy and obtained one month of clinical improve-
ment.
She subsequently presented with progressive decline
in her overall status, including a gradual increase in
pain, macroscopic haematuria, anaemia, and secondary
obstructive clinical symptoms. She was radiated for pallia-
tive/haemostatic purposes in August 2008, with new clinical
improvement. She subsequently died on November 6, 2008
as a result of tumour progression.
3. Conclusion
The combination of clear-cell and transitional adenocar-
cinoma in this case does not allow to assure the role of
each histology in determining the outcome and the poor
response to therapy. Although we can consider that the
metastasic adenopathy was exclusively positive for clear-cell
adenocarcinoma and that the transitional component was
not inﬁltrative, as indications of the responsability of the
clear-cell component in the poor outcome.
In the case of this patient, the disease was not sensitive to
chemotherapy. Although more than 24 months of survival
after diagnosis of metastatic disease is longer than theChemotherapy Research and Practice 3
outcome typically described in the literature, it cannot
be attributed to the chemotherapy treatment, because no
objective response or clinical improvement was observed
when the two lines of chemotherapy were administered.
However, the patient improved on two occasions in response
to the palliative radiotherapy treatment.
From a pathological perspective, a combination of mixed
histology and endometriosis might be of interest because
each of these support one of the two theories concerning
the disease histogenesis. Unfortunately, the fact that the
endometriosis was only in the ovary does not allow to
connect it with the neoplastic disease, and this combination
could be a sporadic association.
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